10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AYTU (Aytu BioScience Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aytu BioScience Inc together

I guess you are interested in Aytu BioScience Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Aytu BioScience Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Aytu BioScience Inc’s Price Targets

I'm going to help you getting a better view of Aytu BioScience Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aytu BioScience Inc

I send you an email if I find something interesting about Aytu BioScience Inc.

1. Quick Overview

1.1. Quick analysis of Aytu BioScience Inc (30 sec.)










1.2. What can you expect buying and holding a share of Aytu BioScience Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$3.89
Expected worth in 1 year
$4.35
How sure are you?
45.0%

+ What do you gain per year?

Total Gains per Share
$0.46
Return On Investment
21.1%

For what price can you sell your share?

Current Price per Share
$2.18
Expected price per share
$1.46 - $2.73
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aytu BioScience Inc (5 min.)




Live pricePrice per Share (EOD)
$2.18
Intrinsic Value Per Share
$-23.17 - $10.26
Total Value Per Share
$-19.28 - $14.14

2.2. Growth of Aytu BioScience Inc (5 min.)




Is Aytu BioScience Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$34.8m$33.7m-$2.9m-9.7%

How much money is Aytu BioScience Inc making?

Current yearPrevious yearGrowGrow %
Making money$409.7k-$3.4m$3.8m935.1%
Net Profit Margin2.4%-15.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Aytu BioScience Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aytu BioScience Inc?

Welcome investor! Aytu BioScience Inc's management wants to use your money to grow the business. In return you get a share of Aytu BioScience Inc.

First you should know what it really means to hold a share of Aytu BioScience Inc. And how you can make/lose money.

Speculation

The Price per Share of Aytu BioScience Inc is $2.18. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aytu BioScience Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aytu BioScience Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.89. Based on the TTM, the Book Value Change Per Share is $0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aytu BioScience Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.4420.4%0.052.1%-0.38-17.5%-0.39-17.8%-1.09-50.0%-0.90-41.3%
Usd Book Value Change Per Share0.4621.1%0.115.3%-0.28-12.9%-0.24-11.2%-0.28-13.0%0.104.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.4621.1%0.115.3%-0.28-12.9%-0.24-11.2%-0.28-13.0%0.104.4%
Usd Price Per Share1.20-2.04-2.55-1.80-2.41-1.83-
Price to Earnings Ratio0.67-1.93--8.38--2.35--1.65--1.33-
Price-to-Total Gains Ratio2.61-4.44-2.85-2.06-1.05-0.25-
Price to Book Ratio0.31-0.62-0.70-0.50-0.40-1.01-
Price-to-Total Gains Ratio2.61-4.44-2.85-2.06-1.05-0.25-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.18
Number of shares458
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.11-0.28
Usd Total Gains Per Share0.11-0.28
Gains per Quarter (458 shares)52.56-129.61
Gains per Year (458 shares)210.25-518.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102102000-518-528
204214100-1037-1046
306316200-1555-1564
408418300-2074-2082
50105110400-2592-2600
60126212500-3111-3118
70147214600-3629-3636
80168216700-4147-4154
90189218800-4666-4672
100210320900-5184-5190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%3.09.00.025.0%3.017.00.015.0%4.036.00.010.0%4.069.00.05.5%
Book Value Change Per Share3.01.00.075.0%5.07.00.041.7%8.011.01.040.0%18.021.01.045.0%24.044.05.032.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%1.00.039.02.5%1.00.072.01.4%
Total Gains per Share3.01.00.075.0%5.07.00.041.7%8.011.01.040.0%18.021.01.045.0%24.044.05.032.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aytu BioScience Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4600.115+301%-0.282+161%-0.244+153%-0.283+161%0.096+381%
Book Value Per Share--3.8883.420+14%3.764+3%4.128-6%7.276-47%4.462-13%
Current Ratio--1.0260.999+3%1.024+0%1.001+2%1.290-20%1.993-49%
Debt To Asset Ratio--0.7190.741-3%0.745-3%0.7210%0.618+16%0.581+24%
Debt To Equity Ratio--2.5592.870-11%2.945-13%2.643-3%1.958+31%2.035+26%
Dividend Per Share----0%-0%-0%-0%0.000-100%
Enterprise Value---60357708.000-49708580.363-18%-60917764.050+1%-60045297.058-1%-44669111.730-26%-22558436.182-63%
Eps--0.4450.045+887%-0.381+186%-0.388+187%-1.090+345%-0.901+302%
Ev To Ebitda Ratio---6.233-2.918-53%-2.415-61%-2.435-61%-1.354-78%-0.832-87%
Ev To Sales Ratio---0.818-0.718-12%-0.651-20%-0.680-17%-0.487-40%0.379-316%
Free Cash Flow Per Share---0.727-0.159-78%0.244-398%-0.172-76%-0.425-41%-0.433-40%
Free Cash Flow To Equity Per Share---0.248-0.062-75%0.029-963%-0.089-64%-0.227-8%0.126-296%
Gross Profit Margin---0.300-1.610+436%9.268-103%3.416-109%2.660-111%1.863-116%
Intrinsic Value_10Y_max--10.256----------
Intrinsic Value_10Y_min---23.165----------
Intrinsic Value_1Y_max---0.441----------
Intrinsic Value_1Y_min---1.844----------
Intrinsic Value_3Y_max---0.205----------
Intrinsic Value_3Y_min---5.987----------
Intrinsic Value_5Y_max--1.380----------
Intrinsic Value_5Y_min---10.587----------
Market Cap19569663.800+45%10772292.00018407419.638-41%22846235.950-53%16222786.275-34%21632565.970-50%16403040.481-34%
Net Profit Margin--0.2160.024+791%-0.154+171%-0.153+170%-0.483+323%-2.880+1431%
Operating Margin----0.0500%-0.0010%-0.0990%-0.2530%-2.6940%
Operating Ratio--0.8191.020-20%1.051-22%1.098-25%1.279-36%3.371-76%
Pb Ratio0.561+45%0.3090.617-50%0.695-56%0.495-38%0.399-23%1.009-69%
Pe Ratio1.225+45%0.6741.931-65%-8.385+1344%-2.346+448%-1.650+345%-1.328+297%
Price Per Share2.180+45%1.2002.043-41%2.545-53%1.804-33%2.408-50%1.826-34%
Price To Free Cash Flow Ratio-0.750-82%-0.413-2.861+593%-25.602+6102%-9.668+2242%-6.346+1437%-3.547+759%
Price To Total Gains Ratio4.735+45%2.6064.444-41%2.853-9%2.056+27%1.054+147%0.254+928%
Quick Ratio--0.7640.722+6%0.634+20%0.672+14%0.900-15%1.608-52%
Return On Assets--0.0320.003+924%-0.026+180%-0.028+186%-0.055+270%-0.124+487%
Return On Equity--0.1140.006+1899%-0.104+191%-0.095+183%-0.143+225%-0.377+430%
Total Gains Per Share--0.4600.115+301%-0.282+161%-0.244+153%-0.283+161%0.096+381%
Usd Book Value--34898000.00030801250.000+13%33788500.000+3%37090500.000-6%65335338.650-47%40065635.325-13%
Usd Book Value Change Per Share--0.4600.115+301%-0.282+161%-0.244+153%-0.283+161%0.096+381%
Usd Book Value Per Share--3.8883.420+14%3.764+3%4.128-6%7.276-47%4.462-13%
Usd Dividend Per Share----0%-0%-0%-0%0.000-100%
Usd Enterprise Value---60357708.000-49708580.363-18%-60917764.050+1%-60045297.058-1%-44669111.730-26%-22558436.182-63%
Usd Eps--0.4450.045+887%-0.381+186%-0.388+187%-1.090+345%-0.901+302%
Usd Free Cash Flow---6524000.000-1434750.000-78%2191250.000-398%-1546916.667-76%-3818034.450-41%-3887888.650-40%
Usd Free Cash Flow Per Share---0.727-0.159-78%0.244-398%-0.172-76%-0.425-41%-0.433-40%
Usd Free Cash Flow To Equity Per Share---0.248-0.062-75%0.029-963%-0.089-64%-0.227-8%0.126-296%
Usd Market Cap19569663.800+45%10772292.00018407419.638-41%22846235.950-53%16222786.275-34%21632565.970-50%16403040.481-34%
Usd Price Per Share2.180+45%1.2002.043-41%2.545-53%1.804-33%2.408-50%1.826-34%
Usd Profit--3994000.000409750.000+875%-3421750.000+186%-3855416.667+197%-10019904.850+351%-7433008.325+286%
Usd Revenue--18452000.00017305750.000+7%23439500.000-21%22258000.000-17%20840470.350-11%11163162.050+65%
Usd Total Gains Per Share--0.4600.115+301%-0.282+161%-0.244+153%-0.283+161%0.096+381%
 EOD+5 -3MRQTTM+23 -14YOY+22 -153Y+18 -195Y+14 -2310Y+15 -24

3.3 Fundamental Score

Let's check the fundamental score of Aytu BioScience Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.225
Price to Book Ratio (EOD)Between0-10.561
Net Profit Margin (MRQ)Greater than00.216
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.764
Current Ratio (MRQ)Greater than11.026
Debt to Asset Ratio (MRQ)Less than10.719
Debt to Equity Ratio (MRQ)Less than12.559
Return on Equity (MRQ)Greater than0.150.114
Return on Assets (MRQ)Greater than0.050.032
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Aytu BioScience Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.245
Ma 20Greater thanMa 502.142
Ma 50Greater thanMa 1001.874
Ma 100Greater thanMa 2001.526
OpenGreater thanClose2.270
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Aytu BioScience Inc

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Fundamental data was last updated by Penke on 2025-07-10 21:52:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Aytu BioScience Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 21.6%Β means thatΒ $0.22 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aytu BioScience Inc:

  • The MRQ is 21.6%. The company is making a huge profit. +2
  • The TTM is 2.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ21.6%TTM2.4%+19.2%
TTM2.4%YOY-15.4%+17.9%
TTM2.4%5Y-48.3%+50.7%
5Y-48.3%10Y-288.0%+239.7%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Aytu BioScience Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 3.2% Return on Assets means thatΒ Aytu BioScience Inc generatedΒ $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aytu BioScience Inc:

  • The MRQ is 3.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 0.3%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.2%TTM0.3%+2.9%
TTM0.3%YOY-2.6%+2.9%
TTM0.3%5Y-5.5%+5.8%
5Y-5.5%10Y-12.4%+7.0%
4.3.1.3. Return on Equity

Shows how efficient Aytu BioScience Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • 11.4% Return on Equity means Aytu BioScience Inc generated $0.11Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aytu BioScience Inc:

  • The MRQ is 11.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 0.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ11.4%TTM0.6%+10.9%
TTM0.6%YOY-10.4%+11.0%
TTM0.6%5Y-14.3%+14.8%
5Y-14.3%10Y-37.7%+23.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aytu BioScience Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Aytu BioScience Inc is operatingΒ .

  • Measures how much profit Aytu BioScience Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aytu BioScience Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-5.0%+5.0%
TTM-5.0%YOY-0.1%-4.9%
TTM-5.0%5Y-25.3%+20.2%
5Y-25.3%10Y-269.4%+244.2%
4.3.2.2. Operating Ratio

Measures how efficient Aytu BioScience Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.82 means that the operating costs are $0.82 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.819. The company is less efficient in keeping operating costs low.
  • The TTM is 1.020. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.819TTM1.020-0.201
TTM1.020YOY1.051-0.031
TTM1.0205Y1.279-0.259
5Y1.27910Y3.371-2.092
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aytu BioScience Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aytu BioScience Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.03Β means the company has $1.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aytu BioScience Inc:

  • The MRQ is 1.026. The company is just able to pay all its short-term debts.
  • The TTM is 0.999. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ1.026TTM0.999+0.026
TTM0.999YOY1.024-0.025
TTM0.9995Y1.290-0.291
5Y1.29010Y1.993-0.704
4.4.3.2. Quick Ratio

Measures if Aytu BioScience Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.76Β means the company can pay off $0.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.764. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.722. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.764TTM0.722+0.042
TTM0.722YOY0.634+0.087
TTM0.7225Y0.900-0.179
5Y0.90010Y1.608-0.708
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aytu BioScience Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Aytu BioScience IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Aytu BioScience Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.72Β means that Aytu BioScience Inc assets areΒ financed with 71.9% credit (debt) and the remaining percentage (100% - 71.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Aytu BioScience Inc:

  • The MRQ is 0.719. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.741. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.719TTM0.741-0.022
TTM0.741YOY0.745-0.005
TTM0.7415Y0.618+0.123
5Y0.61810Y0.581+0.037
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Aytu BioScience Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 255.9% means that company has $2.56 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aytu BioScience Inc:

  • The MRQ is 2.559. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.870. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.559TTM2.870-0.311
TTM2.870YOY2.945-0.075
TTM2.8705Y1.958+0.912
5Y1.95810Y2.035-0.077
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Aytu BioScience Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Aytu BioScience Inc to theΒ Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 0.67 means the investor is paying $0.67Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aytu BioScience Inc:

  • The EOD is 1.225. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.674. Based on the earnings, the company is cheap. +2
  • The TTM is 1.931. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.225MRQ0.674+0.551
MRQ0.674TTM1.931-1.257
TTM1.931YOY-8.385+10.316
TTM1.9315Y-1.650+3.581
5Y-1.65010Y-1.328-0.322
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aytu BioScience Inc:

  • The EOD is -0.750. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.413. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.861. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.750MRQ-0.413-0.337
MRQ-0.413TTM-2.861+2.448
TTM-2.861YOY-25.602+22.740
TTM-2.8615Y-6.346+3.484
5Y-6.34610Y-3.547-2.798
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Aytu BioScience Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.31 means the investor is paying $0.31Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aytu BioScience Inc:

  • The EOD is 0.561. Based on the equity, the company is cheap. +2
  • The MRQ is 0.309. Based on the equity, the company is cheap. +2
  • The TTM is 0.617. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.561MRQ0.309+0.252
MRQ0.309TTM0.617-0.308
TTM0.617YOY0.695-0.078
TTM0.6175Y0.399+0.218
5Y0.39910Y1.009-0.611
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aytu BioScience Inc.

4.8.1. Institutions holding Aytu BioScience Inc

Institutions are holding 27.324% of the shares of Aytu BioScience Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Nantahala Capital Management, LLC17.6140.0518108681200
2025-03-31Stonepine Capital Management Llc7.51550.77364637215617213.7829
2025-03-31Renaissance Technologies Corp1.24510.00017682314001.8562
2025-03-31Armistice Capital, LLC0.93350.00157597-92403-61.602
2025-03-31Geode Capital Management, LLC0.87430539441121126.235
2025-03-31Citadel Advisors Llc0.494203049319431175.6554
2025-03-31Vanguard Group Inc0.45202788800
2025-03-31BlackRock Inc0.369402279300
2025-03-31JAFFETILCHIN INVESTMENT PARTNERS, LLC0.28260.001517437174370
2025-03-31Susquehanna International Group, LLP0.2409014865148650
2025-03-31Acadian Asset Management LLC0.2370.000114622146220
2025-03-31Tower Research Capital LLC0.0760.00024691206978.9092
2025-03-31Mccormack Advisors International0.05790357500
2025-03-31Advisor Group Holdings, Inc.0.0049030000
2025-03-31Morgan Stanley - Brokerage Accounts0.0047029000
2025-03-31UBS Group AG0.00420262-1234-82.4866
2025-03-31Wells Fargo & Co0.002012400
2025-03-31Bank of America Corp0.0017010333
2025-03-31Atlantic Trust Group, LLC0.001308300
2025-03-31SBI Securities Co Ltd0.00106100
Total 30.41220.82831876484+43573+2.3%

4.9.2. Funds holding Aytu BioScience Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Extended Market Index0.51970.000132065-307-0.9484
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.4520.00012788800
2025-04-30Spartan Extended Market Index Pool F0.19770.0002122013072.5811
2025-04-30Fidelity Series Total Market Index0.13050805400
2025-03-31NT Ext Equity Mkt Idx Fd - L0.10230.0001631100
2025-03-31Northern Trust Extended Eq Market Idx0.10230.0001631100
2025-03-31Extended Equity Market Fund K0.057103521110.3134
2025-03-31DFA US Core Equity Class F0.04640.0001286200
2025-04-30Fidelity Total Market Index0.02580158900
2025-03-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.02460.00011516120.7979
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.02440.0001150415040
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.02440.0001150415040
2025-03-31Bridgeway Omni Small-Cap Value N0.02430.0002150000
2025-03-31Bridgeway Omni Small-Cap Value0.02430.0002150000
2025-04-30Dimensional US Core Equity USD Acc0.02170.0006133600
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.02030125200
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.01580975-18-1.8127
2025-03-31Extended Equity Market Fund M0.00710441-15-3.2895
2025-03-31BNYM Mellon SL Market Completion UC10.00610.0001378-1-0.2639
2025-05-31State St US Extended Mkt Indx NL Cl C0.0021012900
Total 1.82890.0021112837+2997+2.7%

5.3. Insider Transactions

Insiders are holding 7.576% of the shares of Aytu BioScience Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-02-28Joshua R DisbrowBUY150001.3
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Net Working Capital  -12,55912,222-337-177-514-481-9952,8011,806
Operating Income  -2,464-1,186-3,6502,720-930-765-1,6954,1162,421



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets124,201
Total Liabilities89,303
Total Stockholder Equity34,898
 As reported
Total Liabilities 89,303
Total Stockholder Equity+ 34,898
Total Assets = 124,201

Assets

Total Assets124,201
Total Current Assets72,512
Long-term Assets51,689
Total Current Assets
Cash And Cash Equivalents 18,173
Net Receivables 35,825
Inventory 11,058
Other Current Assets 7,456
Total Current Assets  (as reported)72,512
Total Current Assets  (calculated)72,512
+/-0
Long-term Assets
Property Plant Equipment 1,657
Intangible Assets 48,711
Long-term Assets Other 1,321
Long-term Assets  (as reported)51,689
Long-term Assets  (calculated)51,689
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities70,706
Long-term Liabilities18,597
Total Stockholder Equity34,898
Total Current Liabilities
Short-term Debt 1,857
Short Long Term Debt 11,885
Accounts payable 12,041
Other Current Liabilities 44,767
Total Current Liabilities  (as reported)70,706
Total Current Liabilities  (calculated)70,550
+/- 156
Long-term Liabilities
Long term Debt 9,535
Long-term Liabilities Other 4,937
Long-term Liabilities  (as reported)18,597
Long-term Liabilities  (calculated)14,472
+/- 4,125
Total Stockholder Equity
Common Stock1
Retained Earnings -313,717
Other Stockholders Equity 348,614
Total Stockholder Equity (as reported)34,898
Total Stockholder Equity (calculated)34,898
+/-0
Other
Capital Stock1
Cash and Short Term Investments 18,173
Common Stock Shares Outstanding 8,204
Liabilities and Stockholders Equity 124,201
Net Debt -16,316
Net Invested Capital 56,318
Net Working Capital 1,806
Property Plant and Equipment Gross 2,347
Short Long Term Debt Total 1,857



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-03-31
> Total Assets 
68
68
68
68
68
60
108
95
82
53
53
43
43
42
30
26
36
27
25
28
28
19
16
14
13
13
12
9
9
10
7
6
13
6
11
10,201
18,227
21,359
24,410
21,986
24,343
20,201
21,506
15,917
14,999
21,246
18,858
23,375
21,060
17,985
42,399
38,338
34,721
31,024
74,478
158,954
152,836
152,836
166,742
271,557
265,668
227,729
223,824
168,826
137,623
150,000
141,436
147,216
136,463
132,888
131,249
128,863
118,095
115,831
116,227
124,201
124,201116,227115,831118,095128,863131,249132,888136,463147,216141,436150,000137,623168,826223,824227,729265,668271,557166,742152,836152,836158,95474,47831,02434,72138,33842,39917,98521,06023,37518,85821,24614,99915,91721,50620,20124,34321,98624,41021,35918,22710,201116136710991213131416192828252736263042434353538295108606868686868
   > Total Current Assets 
0
0
0
30
30
23
69
58
44
18
18
10
13
14
4
1
8
2
1
6
8
2
1
0
0
0
1
1
1
2
1
0
9
2
9
1,650
8,084
11,308
12,765
10,437
10,120
6,364
8,158
4,438
3,029
9,742
7,745
14,595
9,470
6,872
21,977
18,459
15,433
11,983
18,338
83,255
74,966
74,966
92,537
100,013
105,234
89,038
87,540
77,947
59,929
74,415
70,611
78,465
72,832
70,599
71,371
71,130
61,891
60,738
63,053
72,512
72,51263,05360,73861,89171,13071,37170,59972,83278,46570,61174,41559,92977,94787,54089,038105,234100,01392,53774,96674,96683,25518,33811,98315,43318,45921,9776,8729,47014,5957,7459,7423,0294,4388,1586,36410,12010,43712,76511,3088,0841,6509290121110001286128141413101818445869233030000
       Cash And Cash Equivalents 
0
0
0
29
29
23
69
58
44
18
18
10
13
14
3
0
8
2
1
6
7
2
1
0
0
0
1
1
1
2
0
0
9
2
9
1,491
7,353
10,069
10,960
8,666
8,054
2,749
5,230
3,470
802
7,022
3,908
12,006
7,013
3,965
17,805
14,647
11,044
7,014
5,259
62,265
48,082
48,082
62,033
46,538
49,649
40,308
35,277
27,613
19,360
23,811
19,501
19,179
22,985
19,964
19,529
19,760
20,006
20,108
20,398
18,173
18,17320,39820,10820,00619,76019,52919,96422,98519,17919,50123,81119,36027,61335,27740,30849,64946,53862,03348,08248,08262,2655,2597,01411,04414,64717,8053,9657,01312,0063,9087,0228023,4705,2302,7498,0548,66610,96010,0697,3531,4919290021110001276128031413101818445869232929000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,279
0
0
0
0
0
0
1,041
1,769
1,272
75
75
75
76
76
100
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000010010076767575751,2721,7691,0410000005,279000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
157
168
288
84
162
509
582
343
528
1,212
1,377
732
579
760
1,482
1,376
1,741
2,705
6,547
10,203
5,176
5,176
7,001
28,270
28,176
21,626
22,989
27,613
21,712
27,924
25,547
34,043
28,937
29,882
29,403
29,925
23,617
23,159
25,403
35,825
35,82525,40323,15923,61729,92529,40329,88228,93734,04325,54727,92421,71227,61322,98921,62628,17628,2707,0015,1765,17610,2036,5472,7051,7411,3761,4827605797321,3771,21252834358250916284288168157110000000000000110000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
147
534
577
864
1,065
338
750
634
417
386
337
1,079
973
540
837
1,045
905
1,208
882
1,427
1,850
11,709
5,742
10,599
8,629
1,038
10,790
12,716
8,830
8,008
785
624
11,606
868
7,787
9,438
8,252
5,635
11,464
6,167
7,456
7,4566,16711,4645,6358,2529,4387,78786811,6066247858,0088,83012,71610,7901,0388,62910,5995,74211,7091,8501,4278821,2089051,0458375409731,0793373864176347503381,06586457753414700000000000000000000000000000000000
   > Long-term Assets 
0
0
0
38
38
36
38
37
38
35
35
32
30
28
26
25
28
25
24
22
20
17
15
14
0
12
11
9
9
8
7
5
4
3
2
8,551
10,143
10,052
11,645
11,549
14,223
13,837
13,348
11,478
11,970
11,504
11,114
8,780
11,590
11,113
20,422
19,879
19,289
19,041
56,140
75,699
77,871
77,871
74,205
171,544
160,434
138,691
136,284
90,879
77,694
75,585
70,825
68,751
63,631
62,289
59,878
57,733
56,204
55,093
53,174
51,689
51,68953,17455,09356,20457,73359,87862,28963,63168,75170,82575,58577,69490,879136,284138,691160,434171,54474,20577,87177,87175,69956,14019,04119,28919,87920,42211,11311,5908,78011,11411,50411,97011,47813,34813,83714,22311,54911,64510,05210,1438,5512345789911120141517202224252825262830323535383738363838000
       Property Plant Equipment 
0
0
0
38
38
36
38
37
38
35
35
32
30
28
26
25
28
25
24
22
20
17
15
14
12
12
11
9
8
8
6
5
4
3
2
37
30
26
144
197
231
313
292
271
647
567
561
261
219
196
187
219
204
532
497
964
259
893
400
9,340
8,703
8,492
8,139
7,040
6,296
5,648
5,019
4,395
3,869
4,176
3,260
2,762
1,522
1,917
1,694
1,657
1,6571,6941,9171,5222,7623,2604,1763,8694,3955,0195,6486,2967,0408,1398,4928,7039,34040089325996449753220421918719621926156156764727129231323119714426303723456889111212141517202224252825262830323535383738363838000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
74
221
221
221
221
221
74
238
238
238
0
0
0
0
0
0
0
15,387
24,061
28,090
28,090
28,090
65,803
65,802
46,349
46,349
8,637
0
0
0
0
0
0
0
0
0
0
0
0
0000000000008,63746,34946,34965,80265,80328,09028,09028,09024,06115,3870000000238238238742212212212212217474000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,200
0
8,146
8,146
9,699
9,641
11,003
10,885
13,554
13,117
12,680
11,131
11,081
10,696
10,312
8,516
11,366
10,914
20,233
19,658
19,083
18,507
40,254
50,634
48,855
48,855
45,699
96,237
85,464
83,385
81,339
74,428
70,632
69,108
64,985
63,464
58,970
57,341
55,711
54,082
52,453
51,205
49,958
48,711
48,71149,95851,20552,45354,08255,71157,34158,97063,46464,98569,10870,63274,42881,33983,38585,46496,23745,69948,85548,85550,63440,25418,50719,08319,65820,23310,91411,3668,51610,31210,69611,08111,13112,68013,11713,55410,88511,0039,6419,6998,1468,14608,20000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,657
0
398
0
10,113
10,025
11,501
11,352
13,992
13,524
13,056
11,208
11,323
10,937
10,552
3
5
2
2
2
2
2
2
39
33
10
16
0
465
465
457
774
766
829
821
0
792
772
0
0
0
0
0
0
00000077279208218297667744574654650161033392222225310,55210,93711,32311,20813,05613,52413,99211,35211,50110,02510,113039808,65700000000000000000000000000000000
> Total Liabilities 
0
0
0
39
39
41
43
40
44
50
50
52
55
55
61
68
84
83
92
53
66
66
66
69
82
82
94
115
115
121
133
153
50
51
55
9,650
2,610
7,951
9,151
4,420
14,258
13,014
11,059
7,395
10,999
14,893
15,828
10,624
7,636
7,855
22,501
22,301
27,634
28,700
57,387
73,250
57,821
57,821
54,049
128,407
128,100
116,229
118,288
107,682
91,531
96,094
95,619
106,304
97,106
100,721
98,396
98,086
90,379
86,005
85,462
89,303
89,30385,46286,00590,37998,08698,396100,72197,106106,30495,61996,09491,531107,682118,288116,229128,100128,40754,04957,82157,82173,25057,38728,70027,63422,30122,5017,8557,63610,62415,82814,89310,9997,39511,05913,01414,2584,4209,1517,9512,6109,650555150153133121115115948282696666665392838468615555525050444043413939000
   > Total Current Liabilities 
0
0
0
39
39
41
43
40
44
50
50
52
55
55
61
68
84
83
92
53
66
66
66
69
82
82
94
115
115
121
133
153
50
51
55
9,203
1,479
1,778
2,804
3,205
10,104
8,731
6,972
3,354
3,610
3,508
4,801
4,342
3,395
3,587
4,655
4,504
5,373
6,102
15,949
42,033
28,307
28,307
25,813
83,683
109,438
97,997
100,571
80,360
64,442
73,204
67,150
85,416
69,015
65,463
64,187
83,689
62,228
61,252
64,048
70,706
70,70664,04861,25262,22883,68964,18765,46369,01585,41667,15073,20464,44280,360100,57197,997109,43883,68325,81328,30728,30742,03315,9496,1025,3734,5044,6553,5873,3954,3424,8013,5083,6103,3546,9728,73110,1043,2052,8041,7781,4799,203555150153133121115115948282696666665392838468615555525050444043413939000
       Short-term Debt 
0
0
0
34
34
34
34
34
38
49
49
0
55
55
0
0
78
78
0
59
59
52
0
55
68
68
83
96
96
100
105
113
29
31
32
8,514
0
0
1,292
1,221
276
347
80
0
0
0
0
0
0
0
1,677
0
0
79
83
3,907
1,492
1,283
854
7,032
25,542
22,112
24,725
4,688
3,909
9,012
7,519
22,410
0
1,339
39
25,878
4,964
6,127
5,869
1,857
1,8575,8696,1274,96425,878391,339022,4107,5199,0123,9094,68824,72522,11225,5427,0328541,2831,4923,9078379001,6770000000803472761,2211,292008,51432312911310510096968368685505259590787800555504949383434343434000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,700
0
0
0
0
0
5,380
0
4,000
0
0
0
0
0
0
0
0
0
0
0
263
4,559
1,492
1,582
753
6,121
24,602
21,028
23,552
3,485
3,909
9,012
7,519
13,708
1,648
1,277
1,065
16,700
4,252
6,127
5,869
11,885
11,8855,8696,1274,25216,7001,0651,2771,64813,7087,5199,0123,9093,48523,55221,02824,6026,1217531,5821,4924,559263000000000004,00005,380000005,7000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
2
2
3
0
6
0
0
0
0
0
4
3
0
0
3
0
1
5
4
4
0
6
12
7
121
7
13
11
3
0
4
546
1,197
1,075
1,076
1,177
2,323
2,508
2,446
1,409
2,220
1,661
3,415
3,199
2,120
2,112
2,372
2,131
2,134
2,633
9,599
6,956
22,792
11,825
7,157
16,529
19,255
9,383
15,604
11,130
10,987
14,667
10,580
14,673
13,478
14,466
10,473
10,475
10,440
13,513
11,699
12,041
12,04111,69913,51310,44010,47510,47314,46613,47814,67310,58014,66710,98711,13015,6049,38319,25516,5297,15711,82522,7926,9569,5992,6332,1342,1312,3722,1122,1203,1993,4151,6612,2201,4092,4462,5082,3231,1771,0761,0751,1975464031113712171260445103003400000603220000
       Other Current Liabilities 
0
0
0
4
4
5
5
6
1
1
0
52
55
1
57
65
84
5
90
53
7
61
62
9
0
8
82
12
0
14
16
142
18
19
20
571
197
617
1,642
1,943
7,782
6,223
4,526
1,945
1,390
1,847
1,386
1,143
1,275
1,475
593
2,373
3,239
3,390
3,367
30,990
2,193
14,860
17,327
59,940
7,407
66,502
60,242
64,542
49,546
49,425
48,951
48,333
28,606
49,658
53,675
47,336
47,536
41,612
20,161
44,767
44,76720,16141,61247,53647,33653,67549,65828,60648,33348,95149,42549,54664,54260,24266,5027,40759,94017,32714,8602,19330,9903,3673,3903,2392,3735931,4751,2751,1431,3861,8471,3901,9454,5266,2237,7821,9431,64261719757120191814216140128280962617539058465571555201165544000
   > Long-term Liabilities 
0
0
0
0
34
36
34
34
44
48
0
0
0
55
3
3
0
78
3
0
59
4
0
60
0
74
97
104
0
106
124
124
32
31
447
447
1,131
6,173
6,347
1,215
4,153
4,283
4,088
4,041
7,388
11,385
11,027
6,282
4,241
4,267
17,846
17,797
22,261
22,598
41,438
31,217
29,514
29,514
28,236
44,724
18,662
18,232
17,717
27,322
27,089
22,890
28,469
20,888
28,091
35,258
34,209
14,397
28,151
24,753
21,414
18,597
18,59721,41424,75328,15114,39734,20935,25828,09120,88828,46922,89027,08927,32217,71718,23218,66244,72428,23629,51429,51431,21741,43822,59822,26117,79717,8464,2674,2416,28211,02711,3857,3884,0414,0884,2834,1531,2156,3476,1731,13144744731321241241060104977406004590378033550004844343436340000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,825
0
0
0
0
0
0
0
0
0
0
0
0
5,036
5,135
0
0
23,395
8,162
11,171
10,680
9,946
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000009,94610,68011,1718,16223,395005,1355,0360000000000004,8250000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
512
0
469
0
1,091
1,253
1,425
1,205
4,153
4,283
4,087
4,041
7,389
11,385
11,026
6,282
4,241
4,267
12,810
12,662
22,261
22,283
41,146
30,413
28,789
28,465
28,025
24,922
15,858
15,320
14,872
10,749
12,810
9,330
12,465
0
13,378
20,415
0
0
0
0
0
0
00000020,41513,378012,4659,33012,81010,74914,87215,32015,85824,92228,02528,46528,78930,41341,14622,28322,26112,66212,8104,2674,2416,28211,02611,3857,3894,0414,0874,2834,1531,2051,4251,2531,0910469051200000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
396
447
467
613
0
0
213
0
5
3
1
3,818
3,300
120
94
47
26
29
13
11
11
11
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001111111113292647941203,3003,8181350213006134674473960000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
29
29
19
64
55
38
3
0
-10
-12
-14
-32
-42
-48
-56
-67
-24
-38
-48
-49
-55
0
-70
-82
-106
-111
-111
-126
-148
-36
-45
-44
551
15,616
13,409
15,259
17,566
10,085
7,187
10,447
8,521
4,000
6,353
3,031
12,750
13,425
10,130
19,898
16,037
7,088
2,324
17,090
85,704
95,015
95,015
112,693
143,150
137,568
111,500
105,536
61,144
46,092
53,906
45,817
40,912
39,357
32,167
32,853
30,777
27,716
29,826
30,765
34,898
34,89830,76529,82627,71630,77732,85332,16739,35740,91245,81753,90646,09261,144105,536111,500137,568143,150112,69395,01595,01585,70417,0902,3247,08816,03719,89810,13013,42512,7503,0316,3534,0008,52110,4477,18710,08517,56615,25913,40915,616551-44-45-36-148-126-111-111-106-82-700-55-49-48-38-24-67-56-48-42-32-14-12-1003385564192929000
   Common Stock
0
0
0
0
0
0
0
0
205
205
0
0
0
0
0
0
0
1
0
0
0
395
0
2
0
407
412
412
414
414
417
417
540
540
555
4
1
1
1
2
0
1
1
1
0
0
0
4
0
0
1
1
2
2
2
10
13
13
2
2
3
3
3
3
4
6
6
0
1
1
1
1
1
1
1
1
111111110664333322131310222110040001110211145555405404174174144144124124070203950001000000020520500000000
   Retained Earnings Total Equity0000000000000000-159,301-133,841-124,316-120,010-116,865-111,533-111,319-106,390-91,858-87,362-82,704-79,258-79,805-76,987-73,315-69,070-62,319-57,103-52,286-46,561-31,264-23,990-20,658-18,381-12,610-656-6460-619-607-585-569000000-1000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
1
1
1
-1
-23
-1
-1
-1
-1
-1
0
-314
0
0
-47
-471
-481
-493
-53
-511
-531
0
-58
-58
0
0
-63
-63
-53
-53
-5,000
-5,000
-79
-97
-112
-130
-157
-184
-246
-326
-407
-498
-540
-350
-366
-381
-396
-412
-428
0
-484
0
-504
302,451
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000302,451-5040-4840-428-412-396-381-366-350-540-498-407-326-246-184-157-130-112-97-79-5,000-5,000-53-53-63-6300-58-580-531-511-53-493-481-471-4700-3140-1-1-1-1-1-23-1111000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
0
0
0
0
0
0
41
42
43
43
0
47
48
13,157
38,996
39,065
39,247
48,827
56,646
59,472
67,549
70,839
73,069
79,667
80,018
92,552
92,682
92,834
107,258
107,893
113,475
113,640
128,620
202,558
215,013
215,366
246,532
302,448
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000302,448246,532215,366215,013202,558128,620113,640113,475107,893107,25892,83492,68292,55280,01879,66773,06970,83967,54959,47256,64648,82739,24739,06538,99613,157484704343424100000029000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
155
155
157
218
219
220
17
0
225
232
495
243
245
253
259
265
335
342
424
432
438
0
546
449
452
3
102
459
43
10,622
649
47
13,157
38,996
34,065
39,247
48,827
56,646
59,472
67,549
70,839
73,069
79,667
80,018
92,552
93,222
92,834
107,624
107,893
113,475
113,640
129,048
202,558
0
215,013
246,532
302,448
315,864
317,647
323,231
331,912
334,560
345,253
340,289
342,584
0
344,415
345,321
346,132
347,688
348,324
348,475
348,614
348,614348,475348,324347,688346,132345,321344,4150342,584340,289345,253334,560331,912323,231317,647315,864302,448246,532215,0130202,558129,048113,640113,475107,893107,62492,83493,22292,55280,01879,66773,06970,83967,54959,47256,64648,82739,24734,06538,99613,1574764910,6224345910234524495460438432424342335265259253245243495232225017220219218157155155000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue81,002
Cost of Revenue-26,416
Gross Profit54,58654,586
 
Operating Income (+$)
Gross Profit54,586
Operating Expense-60,570
Operating Income-5,254-5,984
 
Operating Expense (+$)
Research Development2,791
Selling General Administrative22,514
Selling And Marketing Expenses26,958
Operating Expense60,57052,263
 
Net Interest Income (+$)
Interest Income0
Interest Expense-4,792
Other Finance Cost-0
Net Interest Income-4,792
 
Pretax Income (+$)
Operating Income-5,254
Net Interest Income-4,792
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-14,0763,568
EBIT - interestExpense = -14,076
-14,076
-11,052
Interest Expense4,792
Earnings Before Interest and Taxes (EBIT)-9,284-9,284
Earnings Before Interest and Taxes (EBITDA)-1,012
 
After tax Income (+$)
Income Before Tax-14,076
Tax Provision-1,768
Net Income From Continuing Ops-15,844-15,844
Net Income-15,844
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses86,256
Total Other Income/Expenses Net-8,8224,792
 

Technical Analysis of Aytu BioScience Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aytu BioScience Inc. The general trend of Aytu BioScience Inc is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aytu BioScience Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aytu BioScience Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aytu BioScience Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.45 < 2.7 < 2.73.

The bearish price targets are: 2.2692 > 1.47 > 1.46.

Know someone who trades $AYTU? Share this with them.πŸ‘‡

Aytu BioScience Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aytu BioScience Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aytu BioScience Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aytu BioScience Inc. The current macd is 0.13119732.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aytu BioScience Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Aytu BioScience Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Aytu BioScience Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aytu BioScience Inc Daily Moving Average Convergence/Divergence (MACD) ChartAytu BioScience Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aytu BioScience Inc. The current adx is 42.61.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aytu BioScience Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Aytu BioScience Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aytu BioScience Inc. The current sar is 1.8300633.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Aytu BioScience Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aytu BioScience Inc. The current rsi is 55.25. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Aytu BioScience Inc Daily Relative Strength Index (RSI) ChartAytu BioScience Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aytu BioScience Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aytu BioScience Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aytu BioScience Inc Daily Stochastic Oscillator ChartAytu BioScience Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aytu BioScience Inc. The current cci is 42.64.

Aytu BioScience Inc Daily Commodity Channel Index (CCI) ChartAytu BioScience Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aytu BioScience Inc. The current cmo is -0.86129217.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Aytu BioScience Inc Daily Chande Momentum Oscillator (CMO) ChartAytu BioScience Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aytu BioScience Inc. The current willr is -55.10204082.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aytu BioScience Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Aytu BioScience Inc Daily Williams %R ChartAytu BioScience Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Aytu BioScience Inc.

Aytu BioScience Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aytu BioScience Inc. The current atr is 0.15488975.

Aytu BioScience Inc Daily Average True Range (ATR) ChartAytu BioScience Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aytu BioScience Inc. The current obv is 79,956,000.

Aytu BioScience Inc Daily On-Balance Volume (OBV) ChartAytu BioScience Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aytu BioScience Inc. The current mfi is 73.00.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Aytu BioScience Inc Daily Money Flow Index (MFI) ChartAytu BioScience Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aytu BioScience Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Aytu BioScience Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aytu BioScience Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.245
Ma 20Greater thanMa 502.142
Ma 50Greater thanMa 1001.874
Ma 100Greater thanMa 2001.526
OpenGreater thanClose2.270
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aytu BioScience Inc with someone you think should read this too:
  • Are you bullish or bearish on Aytu BioScience Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aytu BioScience Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aytu BioScience Inc

I send you an email if I find something interesting about Aytu BioScience Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aytu BioScience Inc.

Receive notifications about Aytu BioScience Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.